الفهرس 
EPIDEMIOLOGYOnly 14 pages are availabe for public view
Abstract
m
iRNAs are now considered a new era for translational and cancer research. There are still too much information that are unknown about the non-coding genetic material that was previously considered as genetic debris and now it has been discovered that it is a key player and a regulator of many functions and genetic pathways.
In our study, we selected 2 miRNAs: miRNA1 and miRNA128. We evaluated their serum levels in 40 patients diagnosed with HCC and 10 persons with no malignancies that were considered as the control group.
We found that the miRNA1 is downregulated in the serum of the HCC group when compared to the control group while the miRNA128 was upregulated. Their diagnostic efficacy was evaluated and it was found that especially the serum level of miRNA128 had a statistically significant high sensitivity and specificity.
We didn’t find in our study any statistically significant difference in the level of our studied miRNAs among the different subgroups in our study population.
We found a statistically significant difference in the OS and PFS according to the serum levels of miRNA1 and miRNA128. The subgroup that had a serum level of miRNA128 higher than 3.2 copies/ul had a worse prognosis and shorter OS and PFS in comparison to those who had a lower level. Unlike our expectations, in our study, the subgroup who had a serum level of miRNA1 higher than 0.6 copies/ul had a worse prognosis with a statistically significant shorter OS and PFS.
We didn’t find any statistically significant difference between the different subgroups when we divided our study group according to the presence of portal vein thrombosis, the presence of lymph nodes metastasis, extrahepatic spread, the age, the gender, the HCV viral load, the antiviral treatment received and the serum AFP level. We only found a difference in the subgroup divided according to the histopathological grade for those who had a biopsy, the CHILD score and the tumor nodularity.